Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Pomalidomide

Drug and asset intelligence for Pomalidomide with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Mechanism of action

Immunomodulator

Recent signals(8)

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for Pomalidomide by Hetero Labs

The FDA has accepted a supplemental application for pomalidomide submitted by Hetero Labs.

RegulatoryJuly 30, 2026

Eugia Pharma submits supplemental application for Pomalidomide (ANDA210249)

Eugia Pharma has submitted a supplemental application for Pomalidomide under ANDA210249, currently marked as AP.

July 30, 2026

FDA Accepts Supplemental Application for Pomalidomide by Teva Pharmaceuticals

Teva Pharmaceuticals has submitted a supplemental application for Pomalidomide, which is currently under review by the FDA.

RegulatoryJuly 30, 2026

FDA Grants Approval for Pomalidomide Supplement by Mylan

The FDA has granted approval for a supplemental application for Pomalidomide submitted by Mylan.

ClinicalJuly 8, 2026

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

A retrospective study will assess clinical outcomes of pomalidomide regimens in relapsed/refractory multiple myeloma.

RegulatoryJuly 7, 2026

EUGIA PHARMA receives AP status for POMALIDOMIDE supplement

EUGIA PHARMA has received an Abbreviated Approval (AP) for a supplement related to POMALIDOMIDE.

RegulatoryJuly 7, 2026

Teva Pharmaceuticals submits supplemental application for Pomalidomide

Teva Pharmaceuticals has submitted a supplemental application for Pomalidomide under ANDA209956.

ClinicalJune 25, 2026

JNJ-68284528 (cilta-cel) vs Standard Therapy in Multiple Myeloma Study Initiated

A study is underway comparing the efficacy of JNJ-68284528 (cilta-cel) against standard therapies in multiple myeloma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Bristol Myers Squibb — Pomalidomide

July 8, 2026 · N/A

Topline Data

Teva — Pomalidomide

July 7, 2026 · N/A

Topline Data

— Pomalidomide

June 25, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Hematology · CAR-T →

Immunomodulator →

Multiple Myeloma →

Oncology · Immunomodulator →

Oncology · Multiple Myeloma →

Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.